Mezzion Pharma Co.,Ltd.

KOSDAQ:A140410 Stock Report

Market Cap: ₩952.8b

Mezzion PharmaLtd Past Earnings Performance

Past criteria checks 0/6

Mezzion PharmaLtd has been growing earnings at an average annual rate of 2%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 4.2% per year.

Key information

2.0%

Earnings growth rate

3.9%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate4.2%
Return on equity-26.5%
Net Margin-101.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Here's Why We're Not Too Worried About Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation

Nov 02
Here's Why We're Not Too Worried About Mezzion PharmaLtd's (KOSDAQ:140410) Cash Burn Situation

Mezzion Pharma Co.,Ltd.'s (KOSDAQ:140410) Shareholders Might Be Looking For Exit

Sep 27
Mezzion Pharma Co.,Ltd.'s (KOSDAQ:140410) Shareholders Might Be Looking For Exit

Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Jun 11
Revenues Not Telling The Story For Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking

Mar 04
Optimistic Investors Push Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Shares Up 26% But Growth Is Lacking

We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon

Feb 05
We Might See A Profit From Mezzion Pharma Co.,Ltd. (KOSDAQ:140410) Soon

Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain

Dec 14
Mezzion PharmaLtd (KOSDAQ:140410) Shareholders Have Enjoyed A Whopping 605% Share Price Gain

Revenue & Expenses Breakdown

How Mezzion PharmaLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A140410 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2414,077-14,22314,552472
30 Jun 2420,246-8,86815,0762,216
31 Mar 2426,090-10,15815,730671
31 Dec 2331,721-12,72816,142939
30 Sep 2332,101-24,49416,8842,825
30 Jun 2331,686-21,35917,1832,587
31 Mar 2331,832-34,59118,4152,545
31 Dec 2230,726-36,29819,5102,217
30 Sep 2230,217-24,67719,4551,956
30 Jun 2229,258-28,43420,7611,652
31 Mar 2227,431-15,57518,1861,956
31 Dec 2126,654-13,60317,2831,956
30 Sep 2130,069-6,22516,332-6,016
30 Jun 2129,776-10,49613,702-3,104
31 Mar 2129,443-12,98114,525-651
31 Dec 2028,634-13,87312,924938
30 Sep 2023,017-26,0935,56319,103
30 Jun 2020,494-23,5388,98616,494
31 Mar 2018,152-22,43511,42913,738
31 Dec 1917,920-23,30114,21812,149
30 Sep 1917,771-15,56022,1252,616
30 Jun 1918,314-16,77219,1934,871
31 Mar 1919,041-20,02117,1679,857
31 Dec 1819,088-18,87613,53311,550
30 Sep 1816,159-23,08711,94314,439
30 Jun 1812,468-20,27010,71613,528
31 Mar 189,170-12,8358,2249,906
31 Dec 175,586-14,8826,83511,093
30 Sep 177,571-8,4156,0877,967
30 Jun 177,785-11,4295,1777,204
31 Mar 178,992-15,6944,9729,721
31 Dec 168,751-12,9854,9877,000
30 Sep 166,299-14,7814,9475,470
30 Jun 166,459-5,7855,8885,769
31 Mar 165,293-1,5914,3232,536
31 Dec 1514,9264,22310,0602,377

Quality Earnings: A140410 is currently unprofitable.

Growing Profit Margin: A140410 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A140410 is unprofitable, but has reduced losses over the past 5 years at a rate of 2% per year.

Accelerating Growth: Unable to compare A140410's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A140410 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22.3%).

Return on Equity

High ROE: A140410 has a negative Return on Equity (-26.45%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 21:49
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mezzion Pharma Co.,Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jae Hoon ShinHanwha Investment & Securities Co., Ltd.
Sang-Hun LeeiM Securities
Seung Kyu JungKiwoom Securities Co., Ltd.